Diagnosing desmoplastic small round cell tumours requires a combination of advanced imaging techniques and specialized tissue analysis. Because this rare cancer often develops silently in the abdomen before causing noticeable symptoms, accurate diagnosis is essential for planning effective treatment strategies.

Introduction: When to Seek Diagnostic Testing

Desmoplastic small round cell tumour, often shortened to DSRCT, is a very rare type of cancer that most commonly develops in the abdomen and pelvic region. Because it affects so few people worldwide—roughly 1 in 1 billion since it was first identified in 1989—many healthcare providers may not immediately recognize its symptoms^[3]. This makes knowing when to seek diagnostic testing particularly important.

Many people with DSRCT do not experience symptoms when the cancer first starts to grow. The tumours can remain silent for some time, developing without obvious warning signs. Later, as the tumours grow larger and begin to affect nearby organs and tissues, symptoms start to appear^[1]. This delayed symptom onset means that by the time many patients realize something is wrong, the disease may already be at an advanced stage.

You should consider seeking medical evaluation if you experience persistent abdominal symptoms that worsen or continue for more than a few days. Common symptoms that might prompt diagnostic testing include pain in the abdomen, swelling or distension of the belly, unexplained weight loss, nausea and vomiting that doesn’t resolve, constipation, diarrhoea, or difficulty urinating^[3][6]. In some cases, people may notice a hard lump in their abdomen, particularly around the belly button area^[6].

Because these symptoms can be caused by many different conditions—some serious and others not—it’s natural to wonder whether they warrant medical attention. While digestive symptoms like nausea or constipation often happen for common, less serious reasons, the key factor is persistence. If these symptoms continue, get worse over time, or occur together with other warning signs like unexplained weight loss or a palpable abdominal mass, it’s time to schedule an appointment with a healthcare provider^[3].

DSRCT most commonly affects young white males between the ages of 10 and 30, though it can occur in anyone^[1][3]. If you fall within this demographic group and experience persistent abdominal symptoms, prompt medical evaluation is especially important. However, because DSRCT can affect people of any age and background, no one should dismiss ongoing symptoms simply because they don’t fit the typical patient profile.

Classic Diagnostic Methods

When you visit a healthcare provider with symptoms that might suggest DSRCT, the diagnostic process typically begins with a thorough physical examination. Your doctor will check for masses or lumps in your belly, paying particular attention to any areas of swelling or tenderness^[3]. The physical exam helps identify obvious abnormalities and guides decisions about what additional tests might be needed.

Imaging Studies

If your doctor suspects DSRCT based on your symptoms and physical examination, imaging scans are the next crucial step. These tests create detailed pictures of the inside of your body, allowing doctors to see tumours, determine their size and location, and check whether the cancer has spread to other areas^[1].

Computed tomography (CT) scans are among the primary imaging tools used to diagnose DSRCT. A CT scan uses X-rays and computer technology to create three-dimensional images of your body. The machine rotates around you while you lie still on a table, taking multiple images from different angles. These images are then combined to show detailed cross-sections of your abdomen and pelvis. CT scans are particularly good at showing the location, size, and number of tumours in the abdominal cavity^[1][3].

Magnetic resonance imaging (MRI) scans use powerful magnets and radio waves instead of radiation to create detailed pictures of soft tissues in your body. MRI scans can provide additional information about tumours and their relationship to nearby organs. Your doctor may order an MRI in addition to a CT scan to get a more complete picture of the disease^[1][3].

Ultrasound testing uses sound waves to create real-time images of the inside of your body. While ultrasound is less detailed than CT or MRI scans, it can be useful as an initial screening tool, especially if you first present with abdominal swelling or a palpable mass. It’s non-invasive, doesn’t use radiation, and can be performed quickly^[1][3].

Positron emission tomography (PET) scans may also be used, particularly to determine whether the cancer has spread to distant parts of the body. During a PET scan, you receive a small amount of radioactive tracer through an injection. Cancer cells absorb more of this tracer than normal cells, making them show up as bright spots on the scan. PET scans help identify areas of active disease that might not be visible on other imaging tests^[1][6].

In some cases, a chest CT scan may be performed to check for spread to the lungs, as DSRCT can sometimes metastasize to the chest area^[6]. The combination of these imaging studies provides a comprehensive map of where tumours are located throughout your body.

Biopsy and Pathological Analysis

While imaging scans can show the presence and location of tumours, they cannot definitively determine what type of cancer you have. To confirm a diagnosis of DSRCT, your doctor must perform a biopsy, which means taking a small sample of tissue from the tumour for detailed examination^[1].

The biopsy sample can be obtained in different ways. A needle biopsy involves inserting a thin needle through your skin into the tumour to extract a small piece of tissue. This is often done with image guidance using ultrasound or CT scanning to ensure the needle reaches the right location. Alternatively, a tissue sample might be collected during a surgical procedure^[1][6].

Once the tissue sample is obtained, it’s sent to a laboratory where a specialist called a pathologist examines it under a microscope. Under microscopic examination, DSRCT cells have a distinctive appearance—they look small and round. These small round cells are arranged in clusters or nests, separated by tough, fibrous tissue called desmoplastic stroma^[1][9].

The pathologist doesn’t stop at just looking at cell shape. DSRCT has unique characteristics that help distinguish it from other types of cancer. The pathologist will perform special staining tests called immunohistochemistry, which check for specific proteins in the tumour cells. DSRCT shows a distinctive pattern called multi-phenotypic differentiation, meaning the cells display markers from different cell types—specifically mesenchymal markers (like desmin), epithelial markers (like cytokeratin), and neural markers (like S100)^[9].

Genetic Testing

The most definitive diagnostic test for DSRCT is genetic testing to identify a specific chromosomal abnormality. DSRCT is caused by changes in certain chromosomes that create an abnormal fusion gene. In this disease, parts of chromosome 11 and chromosome 22 break apart and rejoin incorrectly. This creates a fusion between a gene called EWS (also known as EWSR1) and a gene called WT1^[1][3][6].

This genetic abnormality, technically described as a translocation t(11;22)(p13;q12), produces an abnormal fusion protein called EWS-WT1. This fusion protein is considered pathognomonic for DSRCT, meaning its presence definitively confirms the diagnosis. If this fusion protein cannot be identified in the tissue sample, the diagnosis of DSRCT cannot be made^[9].

Genetic testing looks for this specific chromosomal rearrangement using molecular techniques. The pathologist may check for the EWS-WT1 protein directly using specialized immunohistochemical stains, or they may use molecular genetic tests to identify the gene fusion at the DNA or RNA level^[1][3]. This genetic confirmation is essential because DSRCT can look similar to other types of small round cell tumours under the microscope, and distinguishing between them is crucial for planning appropriate treatment.

Distinguishing DSRCT from Similar Conditions

One of the challenges in diagnosing DSRCT is that it belongs to a family of cancers called small round cell tumours. Under the microscope, several different cancers can have a similar appearance, all showing small, round, undifferentiated cells. Other tumours in this category include Ewing sarcoma, rhabdomyosarcoma, neuroblastoma, and lymphomas^[5].

To distinguish DSRCT from these other conditions, pathologists rely on the combination of multiple diagnostic features. The presence of desmoplastic stroma (the tough, fibrous tissue surrounding the tumour cells) is characteristic of DSRCT. The multi-phenotypic immunohistochemical staining pattern—where the tumour shows markers from epithelial, mesenchymal, and neural cell types—is also distinctive. However, the definitive distinguishing feature is the EWS-WT1 gene fusion, which is found only in DSRCT and not in these other small round cell tumours^[9].

This comprehensive diagnostic approach—combining clinical presentation, imaging findings, microscopic appearance, immunohistochemical staining, and genetic testing—ensures accurate identification of DSRCT and helps rule out other conditions that might require different treatment approaches.

Diagnostics for Clinical Trial Qualification

Because DSRCT is so rare—with only about 200 cases recorded since the cancer was first described in 1989—there is no standardized treatment protocol that applies to all patients^[1]. Clinical trials play an important role in advancing treatment options and improving outcomes for people with this challenging disease. However, enrolling in a clinical trial requires meeting specific diagnostic criteria.

Clinical trials for DSRCT typically have strict eligibility requirements that help ensure the study includes only patients with confirmed disease. The diagnostic requirements for clinical trial qualification generally include all the standard diagnostic procedures described earlier, but with additional emphasis on confirming the molecular diagnosis.

Most clinical trials for DSRCT require confirmed presence of the EWS-WT1 fusion gene or the characteristic chromosomal translocation t(11;22)(p13;q12). This genetic confirmation must be documented through molecular testing of biopsy tissue. Some trials may accept results from standard immunohistochemical testing that shows the EWS-WT1 fusion protein, while others may require more sophisticated molecular genetic testing techniques such as fluorescence in situ hybridization (FISH) or reverse transcription polymerase chain reaction (RT-PCR) to detect the gene fusion^[9].

Beyond genetic confirmation, clinical trials typically require comprehensive imaging documentation showing the extent of disease. This usually includes CT scans of the chest, abdomen, and pelvis to map all tumour locations. Some trials may also require PET scans to assess the metabolic activity of tumours or MRI scans for additional detail about tumour characteristics^[6].

Clinical trials may have specific requirements regarding disease stage or extent. Some trials focus on patients with localized disease that hasn’t spread beyond the abdomen, while others specifically study treatments for metastatic disease that has spread to distant organs. The diagnostic workup for trial qualification must clearly document whether disease is localized or metastatic^[6].

Laboratory tests are another important component of clinical trial qualification. Blood tests assessing organ function—particularly kidney and liver function—are typically required. These tests help determine whether a patient can safely tolerate the experimental treatments being studied. Blood counts are also important, as many cancer treatments affect bone marrow function^[6].

Patients interested in participating in clinical trials should work closely with their medical team to ensure all required diagnostic tests are completed and documented according to trial specifications. Because DSRCT is so rare, patients may need to travel to specialized sarcoma centres that have expertise in treating this disease and conducting relevant clinical trials^[6].